



# New US patent approval for Episurf Medical

Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the United States Patent and Trademark Office (USPTO). The patent, entitled "*Customization of individualized implant*", relates to a system for customizing an implant for treatment of damage in an anatomical joint of a patient.

*"This addresses the process for, in an efficient way, creating optimized, individualized implants for each patient's joint damage, based on Episurf Medical's medical imaging technology. We appreciate this first approval in this patent family"*, comments Katarina Flodström, COO, Episurf Medical.

**For more information, please contact:**

Pål Ryfors, CEO, Episurf Medical  
Tel: +46 (0) 709 62 36 69  
Email: [pal.ryfors@episurf.com](mailto:pal.ryfors@episurf.com)

## About Episurf Medical

*Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's µiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: [www.episurf.com](http://www.episurf.com).*

*This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 09:45 CET on 1 March, 2023.*